Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.74 |
| ▸ | NSD2 | O96028 | 5/20 | 0.61 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.54 |
| ▸ | WHR1 | P49842 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.53 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.52 |
| ▸ | CCR4 | P51679 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334216 | 0.94 | EHMT2 (0.68) | EHMT2NSD2EHMT1WHR1KDM1A | |
| SCHEMBL15280234 | 0.91 | EHMT2 (0.74) | EHMT2NSD2EHMT1WHR1KDM1A | |
| SCHEMBL15280412 | 0.88 | EHMT2 (0.68) | EHMT2NSD2EHMT1WHR1KDM1A | |
| SCHEMBL29613418 | 0.88 | NSD2 (0.76) | EHMT2NSD2EHMT1WHR1KDM1A | |
| SCHEMBL1748471 | 0.88 | NSD2 (0.76) | EHMT2NSD2EHMT1WHR1KDM1A | |
| SCHEMBL15280237 | 0.86 | EHMT2 (0.66) | EHMT2NSD2EHMT1KDM1ARCOR1 | |
| SCHEMBL15280254 | 0.85 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| SCHEMBL29809532 | 0.85 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| SCHEMBL3323652 | 0.85 | EHMT2 (0.81) | EHMT2NSD2EHMT1CCR4 | |
| SCHEMBL31016438 | 0.83 | EHMT2 (0.79) | EHMT2NSD2EHMT1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | EHMT2 2701/4885NSD2 2667/4885EHMT1 2513/4885 |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | EHMT2 4669/4885NSD2 4654/4885EHMT1 4629/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | EHMT2 2701/4885NSD2 2667/4885EHMT1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.